DOCSLIB.ORG

Water Quality Report

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Water Quality Report How does Scottsdale’s advanced treated recycled water measure up to bottled water? Scottsdale’s state-of-the-art water quality lab subjected a leading bottled water brand to the same testing standards used for the recycled water produced at the Advanced Water Treatment Plant. The following list includes testing results for everything that was detected in either water. The table on the reverse lists over 100 additional substances that were tested for and not detected – down to at least the part per million – in either water. ADVANCED TREATED BOTTLED ANALYSIS ANALYTE RECYCLED WATER WATER UNIT Alkalinity, Total 22 144 mg/L Barium, Ba 0.0025 0.0198 mg/L Boron, B 0.20 Not Detected mg/L Calcium Hardness (CaCO3) 2 105 mg/L Calcium, Ca 3 42.1 mg/L Chloride 36 Not Detected mg/L Conductivity 62.2 292 µmho/cm Gross Alpha Not Detected 1.6 pCi/L Magnesium, Mg 1 6.7 mg/L Nitrate, NO3 1.2 * 0.5 mg/L pH 5.4 ** 6.39 Std. units Potassium, K 2 2 mg/L Radium 226 Not Detected <0.4 pCi/L Radium 228 Not Detected <0.7 pCi/L Radium, Combined Not Detected <0.7 pCi/L Residue, Total Dissolved 30 172 mg/L Silica, As SiO2 Not Detected 19.9 mg/L Sodium, Na 34 9 mg/L Strontium, Sr 0.03 0.196 mg/L Sulfate, SO4 12 10 mg/L Total Hardness 11 133 mg/L Total Trihalomethanes 20 ** Not Detected µg/L Turbidity 0.1 0.19 NTU Uranium, Isotopic Not Detected 0.0032 µg/L Asbestos Not Detected Not Tested Cryptosporidium Not Detected Not Tested Giardia Not Detected Not Tested Virus as coliphage Not Detected Not Tested * The EPA maximum contaminant level for nitrate in drinking water is 10 mg/L. ** pH was not adjusted prior to delivery to allow individual breweries flexibility for their specific brewing processes. *** The EPA maximum contaminant level for TTHMs in drinking water is 80 µg/L. mg/L = part per million µg/L= part per billion pCi/L = picoCuries per liter µmho/cm = micro mhos per centimeter The following elements and compounds were tested for and not detected in both the bottled water and the recycled water treated at Scottsdale’s Advanced Water Treatment Plant. 1,1,1-Trichloroethane Chromium, Cr Molybdenum, Mo 1,1,2-Trichloroethane cis-1,2-Dichloroethene Nickel, Ni 1,1-Dichloroethene Cobalt, Co (Non-compliance) Nitrite, NO2 1,2,4-Trichlorobenzene Copper, Cu Nitrogen, Total 1,2-Dichlorobenzene Cotinine Nitrogen, Total Kjeldahl, TKN 1,2-Dichloroethane Cyanide, Total N-Nitrosodimethylamine 1,2-Dichloropropane Dalapon Orthophosphate as P 1,4-Dichlorobenzene DEET Oxamyl 1,4-Dioxane Di(2-ethylhexyl)adipate o-Xylene 2,3,7,8-TCDD (Dioxin) Di(2-ethylhexyl)phthalate Paraquat 2,4,5-T Dibromochloromethane PCB 1016 Aroclor 2,4,5-TP (Silvex) Dibromochloropropane (DBCP) PCB 1221 Aroclor 2,4-D Dicamba PCB 1232 Aroclor 2,4-DB Dichlorprop PCB 1242 Aroclor 3,5-Dichlorobenzoic acid Dieldrin PCB 1248 Aroclor 3-Hydroxycarbofuran Dinoseb PCB 1254 Aroclor Acifluorfen Diquat PCB 1260 Aroclor Alachlor E. coli Pentachlorophenol Aldicarb Endothall Perfluorooctanesulfonic acid Aldicarb Sulfone Endrin Perfluorooctanoic acid (PFOA) Aldicarb Sulfoxide Estradiol Picloram Aldrin Estrone Primidone Aluminum, Al Ethinylestradiol Selenium, Se Antimony, Sb Ethylbenzene Simazine Arsenic, As Ethylene Dibromide (EDB) Styrene Atrazine Fluoride, F Sucralose Baygon Glyphosate Tetrachloroethene Bentazon Heptachlor Thallium, Tl Benzene Heptachlor Epoxide Thiobencarb (ELAP) Benzo(a)pyrene Hexachlorobenzene Thorium, Th Beryllium, Be Hexachlorocyclopentadiene Toluene Bromate Iron, Fe Total coliform Bromodichloromethane Lead, Pb Total DCPA Mono and Di acid Degradate Bromoform Lindane (gamma-BHC) Total PCBs Cadmium, Cd m&p Xylenes Toxaphene Carbamazepine Manganese, Mn trans-1,2-Dichloroethene Carbaryl Meprobamate Trichloroethene Carbofuran Mercury, Hg Triclosan Carbon tetrachloride Methoxychlor Turbidity Carbon, Total Organic, TOC Methiocarb Vanadium, V Chlorade Methomyl Vinyl chloride Chlorobenzene Methylene chloride Xylenes, Total Chloroform Molinate Zinc, Zn.
Load more

Recommended publications
  • Guidelines for the Forensic Analysis of Drugs Facilitating Sexual Assault and Other Criminal Acts
    Vienna International Centre, PO Box 500, 1400 Vienna, Austria Tel.: (+43-1) 26060-0, Fax: (+43-1) 26060-5866, www.unodc.org Guidelines for the Forensic analysis of drugs facilitating sexual assault and other criminal acts United Nations publication Printed in Austria ST/NAR/45 *1186331*V.11-86331—December 2011 —300 Photo credits: UNODC Photo Library, iStock.com/Abel Mitja Varela Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Guidelines for the forensic analysis of drugs facilitating sexual assault and other criminal acts UNITED NATIONS New York, 2011 ST/NAR/45 © United Nations, December 2011. All rights reserved. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. List of abbreviations . v Acknowledgements .......................................... vii 1. Introduction............................................. 1 1.1. Background ........................................ 1 1.2. Purpose and scope of the manual ...................... 2 2. Investigative and analytical challenges ....................... 5 3 Evidence collection ...................................... 9 3.1. Evidence collection kits .............................. 9 3.2. Sample transfer and storage........................... 10 3.3. Biological samples and sampling ...................... 11 3.4. Other samples ...................................... 12 4. Analytical considerations .................................. 13 4.1. Substances encountered in DFSA and other DFC cases .... 13 4.2. Procedures and analytical strategy...................... 14 4.3. Analytical methodology .............................. 15 4.4.
    [Show full text]
  • Forensic Toxicology Laboratory Office of Chief Medical Examiner City of New York
    FORENSIC TOXICOLOGY LABORATORY OFFICE OF CHIEF MEDICAL EXAMINER CITY OF NEW YORK CARISOPRODOL , MEPROBAMATE and TOPIRAMATE by SOLID PHASE EXTRACTION and GAS CHROMATOGRAPHY/MASS SPECTROMETRY (Selected Ion Monitoring) PRINCIPLE Carisoprodol is a carbamate derivative first synthesized in 1959. It is primarily used as a muscle relaxant. UncontrolledMeprobamate is also a carbamate derivative used as a muscle relaxant and the primary metabolite of carisoprodol. Topiramate is a sulfamate-substituted monosaccharide used as an anticonvulsant Carisoprodol, meprobamate and topiramate are quantitated by a selected ion monitoring (SIM) method using methapyrilene as the internal standard. Carisoprodol, meprobamate and topiramate are extracted from biological specimens by solid phase extraction. Drugs are temporarily bound to a sorbent in the solid phase cartridge as the prepared sample is poured through the column. The column is washed to remove interfering compounds, followed by elution of drugs from the column. The eluate is evaporated, reconstituted and injected in the GCMS. Quantitative analysis is performed by SIM GCMS using a six point calibration curve. SAFETY The handling of all biological specimens and reagents is performed within the guidelines which are detailed in the Safety and Health manual. Copy SPECIMEN PREPARATION The procedure is routinely applied to the following biological specimens and their aliquots unless otherwise specified: Blood 0.5 mL of the undiluted specimen Urine 0.5 mL for qualitative identification Brain 0.5 mL of a 1:3 homogenate Gastric Contents 0.5 mL of a 1:10 dilution Liver 0.5 mL of a 1:5 homogenate Vitreous Humor 0.5 mL of the undiluted specimen Bile 0.5 mL of the undiluted specimen Reviewed by: Date: Page 1 of 14 T:\FINALSOP\FINAL SOP PDF\G.
    [Show full text]
  • Assessment of Molecular Action of Direct Gating and Allosteric Modulatory Effects of Carisoprodol (Somartm) on GABA a Receptors
    Graduate Theses, Dissertations, and Problem Reports 2015 Assessment of molecular action of direct gating and allosteric modulatory effects of carisoprodol (SomaRTM) on GABA A receptors Manoj Kumar Follow this and additional works at: https://researchrepository.wvu.edu/etd Recommended Citation Kumar, Manoj, "Assessment of molecular action of direct gating and allosteric modulatory effects of carisoprodol (SomaRTM) on GABA A receptors" (2015). Graduate Theses, Dissertations, and Problem Reports. 6022. https://researchrepository.wvu.edu/etd/6022 This Dissertation is protected by copyright and/or related rights. It has been brought to you by the The Research Repository @ WVU with permission from the rights-holder(s). You are free to use this Dissertation in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you must obtain permission from the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license in the record and/ or on the work itself. This Dissertation has been accepted for inclusion in WVU Graduate Theses, Dissertations, and Problem Reports collection by an authorized administrator of The Research Repository @ WVU. For more information, please contact [email protected]. ASSESSMENT OF MOLECULAR ACTION OF DIRECT GATING AND ALLOSTERIC MODULATORY EFFECTS OF MEPROBAMATE (MILTOWN®) ON GABAA RECEPTORS Manish Kumar, MD, MS Dissertation submitted to the School of Pharmacy at West Virginia University in partial fulfillment of Requirements
    [Show full text]
  • Urine Drug Toxicology and Pain Management Testing
    Urine Drug Toxicology and Pain Management Testing Kara Lynch, PhD, DABCC University of California San Francisco San Francisco, CA Learning Objectives • Describe what chronic pain is, who is affected and how they are commonly treated • Explain the common methodologies used in pain management testing • Interpret urine drug testing results • Create protocols to minimize the occurrence of false positive or false negative results Pain – definition and types • Pain - an unpleasant sensory and emotional experience associated with actual or potential tissue damage • Chronic pain - pain that extends beyond the expected period of healing • Nociceptive Pain – Pain caused by tissue injury – Stimulus-evoked, high intensity – Opioid sensitive • Neuropathic Pain – Caused by nerve injury – Spontaneous activity – Develops in days or month – Opioid insensitive Chronic Pain Patients • Arthritis • Fibromyalgia – Osteoarthritis • Headaches – Rheumatoid arthritis – Migraine – Gout – Tension • Cancer – Cluster • Chronic non-cancer pain • Myofascial pain • Central pain syndrome • Neuropathic pain – CNS damage – Diabetic Peripheral – Multiple Sclerosis Neuropathy – Parkinson’s disease – Postherpetic neuralgia • Chronic abnominal pain • Neck and Back Pain – Intestinal obstructions Chronic Pain Medications • Opiates • Synthetic opioids – Codeine – Fentanyl – Morphine – Methadone • Semi-synthetic opioids – Meperidine – Oxymorphone – Tramadol – Oxycodone – Propoxyphene – Hydromorphone – Levorphanol – Hydrocodone – Tapentadol – Buprenorphine • Anticonvulsant • Muscle
    [Show full text]
  • 2021 Formulary List of Covered Prescription Drugs
    2021 Formulary List of covered prescription drugs This drug list applies to all Individual HMO products and the following Small Group HMO products: Sharp Platinum 90 Performance HMO, Sharp Platinum 90 Performance HMO AI-AN, Sharp Platinum 90 Premier HMO, Sharp Platinum 90 Premier HMO AI-AN, Sharp Gold 80 Performance HMO, Sharp Gold 80 Performance HMO AI-AN, Sharp Gold 80 Premier HMO, Sharp Gold 80 Premier HMO AI-AN, Sharp Silver 70 Performance HMO, Sharp Silver 70 Performance HMO AI-AN, Sharp Silver 70 Premier HMO, Sharp Silver 70 Premier HMO AI-AN, Sharp Silver 73 Performance HMO, Sharp Silver 73 Premier HMO, Sharp Silver 87 Performance HMO, Sharp Silver 87 Premier HMO, Sharp Silver 94 Performance HMO, Sharp Silver 94 Premier HMO, Sharp Bronze 60 Performance HMO, Sharp Bronze 60 Performance HMO AI-AN, Sharp Bronze 60 Premier HDHP HMO, Sharp Bronze 60 Premier HDHP HMO AI-AN, Sharp Minimum Coverage Performance HMO, Sharp $0 Cost Share Performance HMO AI-AN, Sharp $0 Cost Share Premier HMO AI-AN, Sharp Silver 70 Off Exchange Performance HMO, Sharp Silver 70 Off Exchange Premier HMO, Sharp Performance Platinum 90 HMO 0/15 + Child Dental, Sharp Premier Platinum 90 HMO 0/20 + Child Dental, Sharp Performance Gold 80 HMO 350 /25 + Child Dental, Sharp Premier Gold 80 HMO 250/35 + Child Dental, Sharp Performance Silver 70 HMO 2250/50 + Child Dental, Sharp Premier Silver 70 HMO 2250/55 + Child Dental, Sharp Premier Silver 70 HDHP HMO 2500/20% + Child Dental, Sharp Performance Bronze 60 HMO 6300/65 + Child Dental, Sharp Premier Bronze 60 HDHP HMO
    [Show full text]
  • Sedation in Fmri : an Unsolved Challenge
    Sedation in fMRI : An unsolved challenge Byron Bernal *, MD Nolan Altman**, MD There are many medications that can be utilized to sedate children undergoing fMR examinations. The most frequently used drugs are chloral hydrate, thiopenthal, phenobarbital, propofol, and fentanyl. These medications have some secondary effects on the electrical and metabolic activity of the cortex, cerebral blood flow(CBF), cerebral blood volume(CBV), and tissue oxygen extraction. These effects are of no concern in regular MRI (Magnetic Resonance Imaging), however, may have a significant contribution in fMR performed in the sedated child. Since fMRI is based on the hemodynamic and metabolic response of the brain to a given stimulus the selection of the sedation medication seems crucial. The following reviews the current knowledge regarding the relation of these drugs to these physiological parameters. Chloral Hydrate.- Chloral hydrate (CH) does not reduce brain cortex activity. This is demonstrated on EEG where it is widely used. Thoresen M and Henriksen O (1997) did not find changes on the EEGs in 9 out of 13 children with epileptic seizures, before and after CH was administered. We do not know of any reported studies relating CBF, CBV, or cerebral regional metabolism changes, and CH in humans. Propofol.- Propofol has been used as a sedative in children undergoing EEGs. Low propofol doses (0.5- 1 mg/kg) show an increase in the number of beta-waves and a significant reduction of alpha- and theta- waves . Larger doses of propofol (total dose of 2-2.5 mg/kg), the number of beta-waves decreased and delta-waves appeared.
    [Show full text]
  • 2013 National Survey on Drug Use and Health
    140324 Table 1.88C Specific Hallucinogen, Inhalant, Needle, and Heroin Use in Lifetime, by Age Group: Standard Errors of Numbers in Thousands, 2012 and 2013 Total Total Aged 12-17 Aged 12-17 Aged 18-25 Aged 18-25 Aged 26+ Aged 26+ Drug or Method of Administration (2012) (2013) (2012) (2013) (2012) (2013) (2012) (2013) HALLUCINOGENS 674 707 39 35 131 133 641 678 PCP (Angel Dust, Phencyclidine) 311 346 13 8 30 30 309 342 LSD (Acid) 561 580 21 19 87 81 538 567 Peyote 338 328 10 9 31 33 331 327 Mescaline 362 378 7 6 30 35 359 375 Psilocybin (Mushrooms) 524 561 24 22 99 100 502 542 Ecstasy (MDMA) 405 464 30 24 117 114 374 442 INHALANTS 489 519 51 52 84 85 471 505 Amyl Nitrite, Poppers, Locker Room Odorizers, or Rush 311 364 21 18 40 40 306 357 Correction Fluid, Degreaser, or Cleaning Fluid 162 100 26 26 28 26 157 91 Gasoline or Lighter Fluid 184 164 31 28 40 29 174 156 Glue, Shoe Polish, or Toluene 182 175 31 31 32 30 175 168 Halothane, Ether, or Other Anesthetics 89 85 8 10 15 17 88 84 Lacquer Thinner or Other Paint Solvents 132 117 21 18 21 21 130 114 Lighter Gases (Butane, Propane) 91 80 18 15 16 17 89 77 Nitrous Oxide or Whippits 365 409 18 17 71 70 349 399 Spray Paints 123 121 34 24 28 28 115 115 Other Aerosol Sprays 154 130 24 21 33 39 149 121 NEEDLE USE1,2,3 225 265 10 10 38 40 222 261 Heroin Needle Use1,2 162 211 7 6 28 33 161 209 Cocaine Needle Use1,2 160 193 3 1 20 21 158 192 Stimulant Needle Use1,2,3 143 199 4 5 22 26 139 196 Methamphetamine Needle Use1,2,3 134 185 3 5 21 22 131 182 HEROIN 245 281 12 9 43 44 241 278 Smoke Heroin2 153 152 9 5 30 32 148 150 Sniff or Snort Heroin2 203 215 5 5 35 35 203 212 *Low precision; no estimate reported.
    [Show full text]
  • 1,1,1 -Trichloroethane (M E T H Y L C H L O R O F O R M)
    criteria for a recommended standard occupational exposure to 1,1,1 -trichloroethane (m e t h y l c h l o r o f o r m) U.S. DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE Public Health Service Center for Disease Control National Institute for Occupational Safety and Health criteria for a recommended standard.. OCCUPATIONAL EXPOSURE TO 1,1,1 - TRICHLOROETHANE (Methyl Chloroform) U.S. DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE Public Health Service Center for Disease Control National Institute for Occupational Safety and Health JULY 1976 HEW Publication No. (NIOSH) 76-184 PREFACE The Occupational Safety and Health Act of 1970 emphasizes the need for standards to protect the health and safety of workers exposed to an ever-increasing number of potential hazards at their workplace. The National Institute for Occupational Safety and Health has projected a formal system of research, with priorities determined on the basis of specified indices, to provide relevant data from which valid criteria for effective standards can be derived. Recommended standards for occupational exposure, which are the result of this work, are based on the health effects of exposure. The Secretary of Labor will weigh these recommen­ dations along with other considerations such as feasibility and means of implementation in developing regulatory standards. It is intended to present successive reports as research and epide­ miologic studies are completed and as sampling and analytical methods are developed. Criteria and standards will be reviewed periodically to ensure continuing protection of the worker. I am pleased to acknowledge the contributions to this report on 1,1,1-trichloroethane by members of my staff and the valuable, constructive comments by the Review Consultants on 1,1,1-Trichloroethane, by the ad hoc committees of the American Industrial Hygiene Association and the American Academy of Occupational Medicine, and by Robert B.
    [Show full text]
  • 17 Anesthesia for Nonobstetric Surgery During Pregnancy 
    17 Anesthesia for Nonobstetric Surgery During Pregnancy Maternal Safety ....................... 370 Fetal Well-Being ...................... 370 AcuteExposuretoAnesthetics.............. 371 ChronicExposuretoAnesthetics............ 371 EffectofAnestheticsontheFetus............ 372 Sedative and Hypnotic Agents ............ 372 Opioids ......................... 373 Muscle Relaxants ................... 373 Local Anesthetics ................... 373 Oxygen and Carbon Dioxide ............. 374 Inhalation Anesthetics ................. 374 Effects on the Fetal Brain: Behavioral Teratogenicity . 376 Continuation of the Pregnancy .............. 377 Recommendations for Minimizing Chances ofAbortionorPrematureLabor............377 Intrauterine Surgery .................... 379 It has been estimated that every year in the United States about 50,000 pregnant women (0.5–2.2%) will receive anesthesia for various surgical indications during their pregnancy. The purpose of this surgery may be (1) to prolong gestation, (2) unre- lated to the pregnancy, or (3) to correct fetal anomalies. Hence, an understanding of the effects of different anesthetic drugs and techniques on the mother and fetus is essential to the safe administration of anesthesia to pregnant women undergoing surgery. Recently, a question of preoperative pregnancy testing in adolescents has been raised. The authors observed retrospec- tively 412 adolescent women undergoing surgery. The overall incidence of a positive test was 1.2%. The authors concluded that mandatory pregnancy testing is advisable
    [Show full text]
  • FINAL REPORT Evaluation of Healthcare Costs and Utilization
    University of Cincinnati Medical Center College of Pharmacy Health Economics & Outcomes Research FINAL REPORT Evaluation of Healthcare Costs and Utilization among Medicaid Recipients in Schools with School-Based Health Centers SUBMITTED TO THE HEALTH FOUNDATION OF GREATER CINCINNATI by Jeff J. Guo, B.Pharm., Ph.D.1,2 Raymond Jang, Ph.D. 1 Robert J. Cluxton, Pharm.D. 1,2 1 College of Pharmacy 2 Institute of Health Policy and Health Services Research University of Cincinnati Medical Center, Cincinnati, Ohio 3223 Eden Ave. Cincinnati, Ohio Tel. (513) 558-8613 Copyright © 2005 by The Health Foundation of Greater Cincinnati. All rights reserved. To cite this work, please follow this format: Health Foundation of Greater Cincinnati, The (2005). Evaluation of Healthcare Costs and Utilization among Medicaid Recipients in Schools with School-Based Health Centers. Cincinnati, OH: Author. Permission is granted to reproduce this publication provided that these reproductions are not used for a commercial purpose, that you do not collect any fees for the reproductions, that our materials are faithfully reproduced (without addition, alteration, or abbreviation), and that they include any copyright notice, attribution, or disclaimer appearing on the original. Final Report of SBHC Cost Study 2 Table of Contents I. INTRODUCTION ............................................................................................................. 12 Specific Aims and Hypotheses .............................................................................................
    [Show full text]
  • Basic Analytical Toxicology
    The World Health Organization is a specialized agency of the United Nations with primary responsibility for international health matters and public health. Through this organization, which was created in 1948, the health professions of some 190 countries exchange their knowledge and experience with the aim of making possible the attainment by all citizens of the world by the year 2000 of a level of health that will permit them to lead a socially and economically productive life. By means of direct technical cooperation with its Member States, and by stimulating such coopera­ tion among them, WHO promotes the development of comprehensive health services, the prevention and control of diseases, the improvement of environmental conditions, the development of human resources for health, the coordination and development of biomedical and health services research, and the planning and implementation of health programmes. These broad fields of endeavour encompass a wide variety of activities, such as developing systems of primary health care that reach the whole population of Member countries; promoting the health of mothers and children; combating malnutrition, controlling malaria and other communicable diseases including tuberculosis and leprosy; coordinating the global strategy for the prevention and control of AIDS; having achieved the eradication of smallpox, promoting mass immunization against a number of other preventable diseases; improving mental health; providing safe water supplies; and training health personnel of all categories. Progress towards better health throughout the world also demands international cooperation in such matters as establishing international standards for biological substances, pesticides and pharma­ ceuticals; formulating environmental health criteria; recommending international nonproprietary names for drugs; administering the International Health Regulations; revising the International Statistical Classification of Diseases and Related Health Problems and collecting and disseminating healih statistical information.
    [Show full text]
  • August 2021 California Signaturevalue 4 Tier HMO Formulary
    Pharmacy | Formulary | California 2021 California SignatureValue 4-Tier HMO Formulary Please note: This Formulary is accurate as of August 1, 2021 and is subject to change after this date. All previous versions of this Formulary are no longer in effect. Your estimated coverage and copay/coinsurance may vary based on the benefit plan you choose and the effective date of the plan. This Formulary can also be accessed online at myuhc.com > Pharmacy Information > Prescription Drug Lists > California plans > SignatureValue HMO plans. Plan-specific coverage documents may be accessed online at uhc.com/statedruglists > Small Group Plans > California. If you are a UnitedHealthcare member, please register or log on to myuhc.com, or call the toll-free number on your health plan ID card to find pharmacy information specific to your benefit plan. This Formulary is applicable to the following health insurance products offered by UnitedHealthcare: • SignatureValue • SignatureValue Advantage • SignatureValue Alliance • SignatureValue Flex • SignatureValue Focus • SignatureValue Harmony • SignatureValue Performance Updated 6/17/2021 6/21 © 2021 United HealthCare Services, Inc. All Rights Reserved. WF3890815-N Contents At UnitedHealthcare, we want to help you better understand your medication options. ..................................................... 3 How do I use my Formulary? ............................................. 4 What are tiers? ........................................................ 5 When does the Formulary change? ........................................ 5 Utilization Management Programs ......................................... 6 Your Right to Request Access to a Non-formulary Drug ....................... 6 Requesting a Prior Authorization or Step Therapy Exception ................... 7 How do I locate and fill a prescription through a retail network pharmacy? . 7 How do I locate and fill a prescription through the mail order pharmacy? . 7 How do I locate and fill a prescription at a specialty pharmacy? ...............
    [Show full text]